AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05388994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The initial implementation for the 8-week combined exercise program consisted of a progressive aerobic exercise program with a lower extremity bike (Ergoline Ergoselect 200; Ergoline GMBH, Bitz, Germany). All sessions are individually supervised and conducted. Training intensity was started at 70% of maximum aerobic capacity and training intensity was increased by 5% of VO2peak every two weeks. Pedal speed was fixed at 50 rpm throughout 8 weeks of training. Exercise sessions; It started with a 5 minute warm-up period (30% of VO2peak), followed by a total of 40 minutes with a 30-minute load period and a 5-minute cool-down period (without resistance).
Study NCT05817669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod
Description: Patients receiving efgartigimod infusions
Study NCT05817669 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receiving placebo infusions
Study NCT06437080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron III Hydroxide Polymaltose Complex eq. to Elemental Iron, 100 mg
Description: 01 tablet daily for 03 months, This is assigned to Group A.
Study NCT06437080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Carboxymaltose
Description: 03 doses (50 mg iron/mL) per month for 03 months. This is assigned to Group B.
Study NCT05716789 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPR
Description: CPR in cardiac arrest patients
Study NCT05197712 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 25 Baiya SARS-CoV-2 Vax 2
Description: Intramuscular injection in the deltoid region of 0.5 mL/dose of Baiya SARS-CoV-2 Vax 2 (recombinant SARS-CoV-2 receptor-binding domain fused with FC region of human IgG1 vaccine)
Study NCT05197712 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50 Baiya SARS-CoV-2 Vax 2
Description: Intramuscular injection in the deltoid region of 0.5 mL/dose of Baiya SARS-CoV-2 Vax 2 (recombinant SARS-CoV-2 receptor-binding domain fused with FC region of human IgG1 vaccine)
Study NCT05163509 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Unity-based MR-Linac guided Radiotherapy
Description: The radiotherapy was delivered using the Unity-based MR-Linac treatment machine.
Study NCT05040685 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary mapping reverse
Description: At the time of performing the ALND associate the ARM, injecting between 2-5mL of indocyanine green subcutaneously in the ipsilateral upper extremity at the medial inter-muscular and massaged for 5 min. First, identify the ARM nodes by indocyanine green, then perform conventional axillary lymphadenectomy trying to preserve the ARM nodes. And, in a second time, extract ARM nodes for their individualized anatomopathological study.
Study NCT04932824 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCB-2019
Description: a Recombinant SARS-CoV-2 Trimeric S-Protein Subunit Vaccine for COVID-19.
Study NCT04216589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Administered subcutaneously
Study NCT05015621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Surufatinib plus Toripalimab
Description: Surufatinib is a tablet in the form of 50mg, oral, once a day; Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
Study NCT05015621 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 5-fluorouracil, Calcium folinate and Irinotecan
Description: Irinotecan 180 mg/m\^2, Calcium folinate 400 mg/m\^2, 5-FU total 2800 mg/m\^2 will be administrated once two weeks.
Study NCT04933916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMB-001
Description: Combination product metyrapone and oxazepam
Study NCT05002959 — intervention group
Intervention type: DEVICE
Intervention: Anatomic TESS V3
Description: Implantation of the T.E.S.S.® V3 Modular Total Shoulder System, Anatomic configuration.
Study NCT05002959 — intervention group
Intervention type: DEVICE
Intervention: Reverse TESS V3
Description: Implantation of the T.E.S.S.® V3 Modular Total Shoulder System, Reverse configuration.
Study NCT05908435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dispensers, Flyers, Enhanced Signage + a social media component delivered by teen ambassadors
Description: The study intervention is designed to increase utilization of free sunscreen dispensers, applying and reapplying sunscreen, and motivating use of other forms of sun protection by teens. IMPACT Melanoma will install and maintain free sunscreen dispensers at the study sites. Flyers will be posted at locations at the park/beach to inform people of the availability of free sunscreen and the location of the dispenser. 'Teen enhanced' signage will be present on the dispenser in the intervention parks/beaches. Teen ambassadors will share 3-5 posts to their social media platform over the course of 1 week encouraging sun protection practices and use of the free sunscreen dispenser (when the intervention is occurring at the study site).
Study NCT06410495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NiteCAPP SINCC
Description: Standard CBT-I techniques along with modules targeting noncompliance in children with ODD and their parents.
Study NCT05249114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib tablets are supplied as film coated tablets containing cabozantinib malate equivalent to 20 mg and 60 mg of cabozantinib and contain microcrystalline cellulose, lactose anhydrous, hydoxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry yellow. The 60 mg tablets are oval and the 20 mg tablets are round. Doses of 40 mg will comprise two 20-mg tablets.
Study NCT05249114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu-177
Description: Currently, the only FDA-approved PRRT consists of dotatate, a somatostatin analogue, radiolabeled with Lutetium-177 (Lu177), a beta-minus emitter (brand name Lutathera). Lu177 induces cell death via DNA strand breaks, caspase-3 apoptosis, and interfering with DNA-PK expression (which is associated with DNA repair). PRRT with Lu-177 DOTATATE is a targeted, intravenous therapy inducing DNA damage by delivering ionizing radiation to somatostatin receptor positive tumors.
Study NCT06197503 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conduction system pacing
Description: Left bundle branch pacing or His bundle branch pacing
Study NCT06197503 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right ventricular pacing
Description: Conventional pacing
Study NCT05137847 — intervention group
Intervention type: DRUG
Intervention: Remitoro
Description: Intravenous infusion.
Study NCT05222022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Retitrack
Description: Retitrack device measures and analyzes eye movement
Study NCT04905732 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NHFOV
Description: After documenting parental consent, the ventilated infants with BPD were randomly assigned to NHFOV
Study NCT04905732 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP
Description: After documenting parental consent, the ventilated infants with BPD were randomly assigned to NCPAP
Study NCT04775342 — intervention group
Intervention type: DEVICE
Intervention: smartphone
Description: modern technology
Study NCT05519137 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active lighting intervention
Description: Lighting intervention designed to impact the circadian system
Study NCT05519137 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control lighting intervention
Description: Lighting intervention designed to have no impact on the circadian system
Study NCT05397171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8853
Description: Monotherapy given until progressive disease or upon meeting other discontinuation criteria.
Study NCT05397171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zirconium-89 crefmirlimab berdoxam
Description: CD8+ T cell tracer for positron emission tomography (PET) at two time points in addition to monotherapy AZD8853
Study NCT05542407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 10 mg/kg- 20 mg/kg Atezolizumab will be administered by intravenous, on day 1 of each 21-day cycle.
Study NCT05542407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: 375 mg once weekly - 625 mg ONC201 will be administered orally, once or twice weekly.
Study NCT05022602 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imagio
Description: Imagio - both ultrasound probe and Duplex OA probe
Study NCT04908215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INM-755 (cannabinol) cream
Description: topical cream containing cannabinol for dermal application
Study NCT04908215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: topical cream base for dermal application containing no active agent
Study NCT05292417 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionation Radiotherapy
Description: Patients will receive radiation to the target lesion at a dose of 5Gy, 5 fractions a week, or a dose of 8Gy, 3 fractions a week. The course last once or twice depending on the investigator.
Study NCT05292417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab
Description: 200 mg per IV infusion every 21 days until disease progression or participant withdrawal from study or last for two years
Study NCT05292417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 200µg given 7-14 days(until WBC≥40x109/L), every 21 days until disease progression or participant withdrawal from study or last for two years.
Study NCT05292417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib will be given 5mg qd for 2 weeks on and 1 week off, Q3W.
Study NCT05169112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lupron Depot
Description: Patients randomized to receive androgen deprivation therapy (ADT) will receive 12 months of Lupron Depot (22.5 mg) administered every 3 months
Study NCT05221268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Level walking exercise
Description: treadmill exercise with 0 inclination
Study NCT05221268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Downhill exercise
Description: treadmill exercise with -20 inclination
Study NCT06376136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8010 for Injection
Description: Intravenous
Study NCT06376136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1006 for Injection
Description: Intravenous
Study NCT06265701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Derailment-Focused Reflective Journaling
Description: Experimental group aimed at decreasing anxiety symptoms
Study NCT06265701 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Everyday Tasks Reflective Journaling
Description: Control group
Study NCT04442451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Exercise
Description: Each participant will attend 3 sessions per week for 8 weeks. Participants will perform low-load knee extension resistance training (20% of 1-RM) without blood flow restriction on the designated leg for 4 sets of contractions with 15 contractions per set of contractions with a 30 second rest between each set of contractions.
Study NCT04442451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Exercise
Description: Each participant will attend 3 sessions per week for 8 weeks. Participants will perform low-load knee extension resistance training (20% of 1-RM) with blood flow restriction on the designated leg for 4 sets of contractions with 15 contractions per set of contractions with a 30 second rest between each set of contractions.
Study NCT05718427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ayres Sensory Integration Therapy
Description: Ayres sensory integration theory provides evidence from basic and applied science about the ability to receive, sort, process, and make use of the information originating from the body and the environment and perceived by our senses (touch, gravity, body position and movement, sight, smell, hearing, taste). This sensory information goes to the brain, where it is organized and interpreted. As a result, we form a plan of action that allows us to have an adaptive response appropriate for the demands of the environment. A thorough assessment guides the preparation of goals addressing the referring concerns and the recommendations for intervention. Ayres Sensory Integration intervention is provided within the context of professional practice. It is designed to improve sensory perceptual abilities, self-regulation, motor skills, and praxis. In doing so, it supports the client's ability to show improved behavior, learning, and social participation.
Study NCT06579937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine hydrochloride
Description: During anesthesia induction, a 0.2 mg/kg esketamine bolus was administered intravenously.
Study NCT06579937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: During anesthesia induction, a bolus of equal 0.9% saline was administered intravenously.
Study NCT06459505 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine or standard Physical Therapy
Description: Participants will undergo physical therapy to stop abnormal movement patterns and restore control over output in the developmental sequence. Therapists will provide cues to elicit basic posture and movement patterns, inhibiting aberrant patterns. The therapy aims to promote normal posture and movement patterns, incorporating the hemiplegic side for symmetry and functional use. Active usage and targeted strengthening activities will be emphasized, with motor performance practice included.
Study NCT06459505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity
Description: For Upper extremities, Manual Ability Classification Scale (MACS) is a tool designed to support individuals with hemiplegic cerebral palsy by providing structured support through activities focusing on strength, flexibility, balance, and coordination. Participants at different MACS levels receive tailored treatments, including adaptive tools, task-specific training, assistive gadgets, and functional training. For lower extremities, the therapy will begin on stable support surfaces before progressing to more challenging surfaces such as inflatable cushions, foam pads, or balance discs, focusing on slow and controlled motions for improved body alignment and coordination.
Study NCT04604275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucrase
Description: 1 mL (8,500 I.U.) (one full measuring scoop or 28 drops) per meal or snack for patients up to 15 kg in body weight. 2 mL (17,000 I.U.) for patients over 15kg in body weight. Dosage is 1 or 2 mL (8,500 to 17,000 I.U.) taken orally or by g-tube with each meal or snack diluted in water, milk, or infant formula.
Study NCT04604275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 mL of placebo per meal or snack for patients up to 15 kg in body weight. 2 mL of placebo per meal of snack for patients above 15kg in body weight. Dosage is 1 or 2 mL of placebo taken orally or by g-tube with each meal or snack diluted in water, milk, or infant formula.
Study NCT05190211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation exercise program
Description: TGr will be given online exercises, synchronized 2 days a week, and a home program for 1 day, accompanied by a physiotherapist, via videoconference on the group smartphone.
Study NCT05190211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videobased exercise program
Description: After 1 session of online simultaneous exercise training in the company of a physiotherapist via videoconference on the smart phone, an exercise video including the exercises will be sent to them and the patients will be asked to do their exercises 3 days a week. The subjects will be asked to keep an exercise diary and the status of the diaries will be followed by calling them once a week.
Study NCT06288399 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given
Study NCT05350332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Ventilator
Description: The negative pressure ventilator is an off-the-shelf FDA-approved device designed to treat respiratory patients with hypoventilation syndromes. This ventilator places the torso within a fixed container that is connected to a vacuum source, which inflates the lungs by pulling a negative pressure around the chest and abdomen. After the clinically routine DISE, a negative pressure ventilator will be placed on the participant's chest to increase lung volumes and the DISE evaluation will be repeated to observe changes.
Study NCT05350332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulmonary Function Testing (PFT)
Description: PFT is a routine standardized clinical test evaluating lung function, consisting of two parts: spirometry and body plethysmography. In spirometry, participants breathe through a mouthpiece that measures airflow and volume to determine normal and maximal volume of inspiration/expiration. Body plethysmography is performed to calculate residual lung volumes. Participants enter in an enclosed chamber where they breathe through a mouthpiece. Changes in pressure in the sealed chamber during breathing are used to calculate the volume of air that remains in the lung after expiration. A MiniBox+ device may be used. The MiniBox+ device derives total lung capacity (TLC) during tidal breathing by the analysis of gas pressures and airflows immediately preceding and immediately following airway occlusions to calculate the same measures as conventional PFT analysis.
Study NCT05350332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Phrenic Nerve Stimulation
Description: Phrenic nerve stimulation (PNS) will be performed transcutaneously using a commercially available and FDA approved peripheral neurostimulator. (Digitimer DS8R Bipolar Constant Current Stimulator). The neurostimulator consists of a stimulation generating box connected to electrodes that will be placed over the skin of the neck bilaterally over both phrenic nerves where an bipolar electric current will be used to stimulate the phrenic nerve leading to diaphragm contraction.
Study NCT05168332 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: patellar taping combined with isometric strength training
Description: patellar taping combined with isometric strength training
Study NCT05168332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patellar taping combined with isometric strength training
Description: patellar taping combined with isometric strength training
Study NCT05168332 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: sham patellar taping combined with isometric strength training
Description: sham patellar taping combined with isometric strength training
Study NCT05168332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sham patellar taping combined with isometric strength training
Description: sham patellar taping combined with isometric strength training
Study NCT05260385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KC1036
Description: KC1036 are administered orally QD or BID in 21-day cycles.
Study NCT05386277 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TufTex Single Lumen Embolectomy Catheter
Description: The SLC Embolectomy Catheter is indicated for the removal of arterial emboli and thrombi
Study NCT05759520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (multivalent conjugate)
Description: the 2-month-old experimental group and the 3-month-old group received the experimental vaccine
Study NCT05759520 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13
Description: the 2-month-old control group received the active control vaccine
Study NCT05963386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-EB-FAPI radionuclide therapy
Description: radionuclide therapy using 177Lu-DOTA-EB-FAPI 90 mCi (3.3 GBq) will be performed 6-weekly. A maximum of 4 cycles will be administered.
Study NCT06443398 — intervention group
Intervention type: OTHER
Intervention: There is no intervention in the study
Description: There is no intervention in the study
Study NCT06145581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Care (home-based physical activity)
Description: Receive health coaching
Study NCT06145581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participate in home-based physical activity
Study NCT06145581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telephone interview
Description: Participate in a telephone interview
Study NCT06145581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Monitoring
Description: Undergo remote monitoring
Study NCT06145581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient Monitoring
Description: Monitor physical activity
Study NCT06145581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06145581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies